CMS Grants NTAP Status to Omeros' YARTEMLEA, Boosting Medicare Reimbursement
Event summary
- CMS granted New Technology Add-On Payment (NTAP) status to YARTEMLEA® under the FY 2027 IPPS Final Rule.
- Eligible hospitals treating Medicare patients with YARTEMLEA for TA-TMA will receive up to $287,079 in additional reimbursement per patient starting October 1, 2026.
- YARTEMLEA is the first and only FDA-approved treatment for hematopoietic stem cell transplant-associated thrombotic microangiopathy (TA-TMA).
- Approximately 30% of patients undergoing allogeneic HCT in the U.S. are Medicare beneficiaries.
The big picture
CMS’s NTAP designation for YARTEMLEA addresses a critical barrier to adoption in the Medicare population, where reimbursement constraints often limit access to innovative therapies. This move aligns with broader trends in healthcare policy aimed at accelerating the uptake of breakthrough treatments for rare diseases. Omeros’ ability to leverage this decision could set a precedent for other biotech firms targeting underserved patient segments.
What we're watching
- Hospital Adoption
- How NTAP status will affect hospital adoption rates for YARTEMLEA among Medicare patients.
- Regulatory Pathways
- Whether Omeros can secure similar reimbursement benefits in other markets, particularly Europe.
- Market Expansion
- The pace at which Omeros can expand YARTEMLEA's use beyond TA-TMA into other complement-mediated diseases.
Related topics